Electromedical, a bioelectronic medical device company, recently shared updates with their shareholders about their recent accomplishments and strategic advancements. The company reported a 17% increase in revenue for the year ending in 2023 compared to the previous year. They also announced a strategic partnership with Lionheart Health, a recipient of the Abbvie Allergan Aesthetics ULP Golden Passport Award and a participant in the $101 million XPRIZE competition. Additionally, Electromedical completed the development of their Wellness Pro Infinity™ device, which incorporates iDNA technology and Digital Synthesis.
The company also highlighted financial improvements, including renegotiated creditor agreements that may benefit current and potential investors. Electromedical opened pre-order sign-ups for the Wellness Pro Infinity™, with shipping expected between September and October. They received a significant purchase order from Lionheart Health and onboarded a medical group with 200 sales reps to introduce the device to medical professionals and clinics across the United States.
EMED’s CEO, Mathew Wolfson, emphasized the importance of their partnership with Lionheart Health in expanding the reach of the Wellness Pro Infinity™. He stated that this collaboration would make the groundbreaking technology more accessible to clinicians and patients nationwide. The integration of the device into Lionheart’s ‘MedSpas’ is a significant step towards providing non-invasive pain management solutions that are effective and widely available.
The successful completion of the Wellness Pro Infinity™ development represents a significant milestone for Electromedical in advancing bioelectronic medical devices. The company’s engineering team overcame challenges during the development process, ensuring the device’s precision and capabilities meet industry standards. With features like iDNA technology and Digital Synthesis, the Wellness Pro Infinity™ sets a new benchmark in electrotherapy and bioelectronics.
In terms of financial outlook, Electromedical announced positive progress in renegotiating agreements with creditors and eliminating warrants and restrictive clauses. The company launched pre-order sign-ups for the Wellness Pro Infinity™ and received a substantial purchase order from Lionheart Health. To further drive sales growth, Electromedical added 200 professional medical device sales representatives to their team, expanding their market reach across the United States.
CEO Matthew Wolfson expressed confidence in Electromedical’s ability to transform pain treatment methods for patients, doctors, clinics, and hospitals. He highlighted the company’s commitment to delivering innovative medical devices that enhance patient care and provide new treatment options for medical professionals. Electromedical is focused on sustaining financial stability while creating value for shareholders and contributing to the healthcare landscape.
Overall, Electromedical Technologies, Inc. is dedicated to providing pain management solutions through cutting-edge frequency-based medical devices. The company’s innovative approach and strategic partnerships demonstrate their commitment to advancing bioelectronic medicine and improving patient outcomes. With a strong financial foundation and a focus on innovation, Electromedical is poised to make a meaningful impact on the healthcare industry.